What does MA-EL RX do?

MA-EL RX is a specialist medical practice in Braine-l'Alleud. Private Limited, started on 16 June 2003, 1 establishment.

What is the address of MA-EL RX?

The registered office of MA-EL RX is located at Av la Douce Colline 22, 1420 Braine-l'Alleud.

Is MA-EL RX still active?

Yes. According to the CBE (29 October 2026) MA-EL RX is active, legal situation “Normale toestand”, started on 16 June 2003.

Is MA-EL RX registered on Peppol?

No, MA-EL RX is currently not registered on the Peppol network.

What is the enterprise number of MA-EL RX?

The enterprise number of MA-EL RX is BE0859704565.

When was MA-EL RX founded?

MA-EL RX was founded on 16 June 2003.

Who are the directors of MA-EL RX?

According to the 2025 annual accounts, the directors of MA-EL RX are: Marie LORENT, Béatrice BOUCHE.

Is MA-EL RX a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 16 June 2003; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did MA-EL RX make in 2025?

MA-EL RX posted a profit after taxes of € 110,203 in financial year 2025.

What is the revenue of MA-EL RX?

As a small company, MA-EL RX is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 187,193.

How many employees does MA-EL RX have?

According to the 2025 annual accounts, MA-EL RX has 0.2 full-time equivalents (FTE).

MA-EL RX (Private Limited) - Braine-l'Alleud

Dossier MA-EL RX, printed on 29 October 2026 from databakkes.be/en/0859704565/ma-el-rx. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Not on Peppol Peppol

Not registered in the Peppol network, mandatory for VAT-liable companies since 1 January 2026.

Financials

Financial year 2025

MA-EL RX from Braine-l'Alleud, company number BE0859704565, closed financial year 2025 with a result of € 110,203 after tax. For that financial year MA-EL RX recorded a gross margin of € 187,193 and equity of € 505,519. Compared with financial year 2024, the result moved from € 74,181 to € 110,203. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 13, 2026.

What it is worth Growing

€ 505,519

▲ 20% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 110,203

▲ 49% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 121,812

▼ 33% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 27,448 paid out

25 % of the profit went to the shareholders, the rest stayed in the company.

People and assets in 2025

Full-time equivalents

0.2

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 11,941

▲ 1% vs 2024

Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 1,607

▲ 94% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

€ 1,399

▼ 87% vs 2024

Loans from banks and other lenders, long and short.

Owed to suppliers

€ 18,830

▲ € 15,988 vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 38,185

▲ 265% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 117,257 Gross margin 2022: € 117,257 First fiscal year in the series	€ 292,446 Gross margin 2023: € 292,446 ▲ 149% vs 2022 (€ 117,257) Favourable step	€ 143,732 Gross margin 2024: € 143,732 ▼ 51% vs 2023 (€ 292,446) Unfavourable step	€ 187,193 Gross margin 2025: € 187,193 ▲ 30% vs 2024 (€ 143,732) Favourable step	▲ 30%
Profit after taxes	€ 49,449 Profit after taxes 2022: € 49,449 First fiscal year in the series	€ 169,819 Profit after taxes 2023: € 169,819 ▲ 243% vs 2022 (€ 49,449) Favourable step	€ 74,181 Profit after taxes 2024: € 74,181 ▼ 56% vs 2023 (€ 169,819) Unfavourable step	€ 110,203 Profit after taxes 2025: € 110,203 ▲ 49% vs 2024 (€ 74,181) Favourable step	▲ 49%
Equity	€ 207,778 Equity 2022: € 207,778 First fiscal year in the series	€ 376,797 Equity 2023: € 376,797 ▲ 81% vs 2022 (€ 207,778) Favourable step	€ 422,764 Equity 2024: € 422,764 ▲ 12% vs 2023 (€ 376,797) Favourable step	€ 505,519 Equity 2025: € 505,519 ▲ 20% vs 2024 (€ 422,764) Favourable step	▲ 20%
Total debts	€ 116,903 Total debts 2022: € 116,903 First fiscal year in the series	€ 137,255 Total debts 2023: € 137,255 ▲ 17% vs 2022 (€ 116,903) Unfavourable step	€ 29,377 Total debts 2024: € 29,377 ▼ 79% vs 2023 (€ 137,255) Favourable step	€ 70,059 Total debts 2025: € 70,059 ▲ 138% vs 2024 (€ 29,377) Unfavourable step	▲ 138%
Cash	€ 9,785 Cash 2022: € 9,785 First fiscal year in the series	€ 206,841 Cash 2023: € 206,841 ▲ € 197,056 vs 2022 (€ 9,785) Favourable step	€ 180,979 Cash 2024: € 180,979 ▼ 13% vs 2023 (€ 206,841) Unfavourable step	€ 121,812 Cash 2025: € 121,812 ▼ 33% vs 2024 (€ 180,979) Unfavourable step	▼ 33%
Retained profit	€ 195,378 Retained profit 2022: € 195,378 First fiscal year in the series	€ 364,397 Retained profit 2023: € 364,397 ▲ 87% vs 2022 (€ 195,378) Favourable step	€ 410,364 Retained profit 2024: € 410,364 ▲ 13% vs 2023 (€ 364,397) Favourable step	€ 493,119 Retained profit 2025: € 493,119 ▲ 20% vs 2024 (€ 410,364) Favourable step	▲ 20%
Dividend	€ 800 Dividend 2022: € 800 First fiscal year in the series	€ 800 Dividend 2023: € 800 Unchanged (€ 800) Unchanged	€ 28,215 Dividend 2024: € 28,215 ▲ € 27,415 vs 2023 (€ 800) Unchanged	€ 27,448 Dividend 2025: € 27,448 ▼ 3% vs 2024 (€ 28,215) Unchanged	▼ 3%
Bank debt	€ 55,575 Bank debt 2022: € 55,575 First fiscal year in the series	€ 36,236 Bank debt 2023: € 36,236 ▼ 35% vs 2022 (€ 55,575) Favourable step	€ 11,009 Bank debt 2024: € 11,009 ▼ 70% vs 2023 (€ 36,236) Favourable step	€ 1,399 Bank debt 2025: € 1,399 ▼ 87% vs 2024 (€ 11,009) Favourable step	▼ 87%
Balance sheet total	€ 324,681 Balance sheet total 2022: € 324,681 First fiscal year in the series	€ 514,052 Balance sheet total 2023: € 514,052 ▲ 58% vs 2022 (€ 324,681) Unchanged	€ 452,141 Balance sheet total 2024: € 452,141 ▼ 12% vs 2023 (€ 514,052) Unchanged	€ 575,579 Balance sheet total 2025: € 575,579 ▲ 27% vs 2024 (€ 452,141) Unchanged	▲ 27%
Employees (FTE)	-	0.2 Employees (FTE) 2023: 0.2 First fiscal year in the series	0.2 Employees (FTE) 2024: 0.2 Unchanged (0.2) Unchanged	0.2 Employees (FTE) 2025: 0.2 Unchanged (0.2) Unchanged

Key figures of MA-EL RX, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to MA-EL RX?

What happened at MA-EL RX in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 13, 2026 New annual accounts for financial year 2025: profit of € 110,203 (▲ 49% vs 2024). Source: NBB ↗
2025 Marie LORENT became a director. NBB
2003 Béatrice BOUCHE became a director. NBB
Jun 16, 2003 New establishment in Schaarbeek. KBO
Jun 16, 2003 Start of the company according to the CBE. KBO

In short

From € 49,449 profit in 2022 to € 110,203 profit in 2025.

Paid € 200,051 in corporate taxes since 2022.

Best year ever: 2023, with € 169,819 profit.

Paid out € 57,263 in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

Marie LORENT

Béatrice BOUCHE

MA-EL RX

centre de radiodiagnostic medicis 33%

Behind MA-EL RX are Marie LORENT and Béatrice BOUCHE. It owns 33% of centre de radiodiagnostic medicis itself.

Directors

According to the 2025 annual accounts

Marie LORENT

Director

since 2025

Béatrice BOUCHE

Director

Also active at: CENTRE DE RADIODIAGNOSTIC MEDICIS

since 2003

Establishments

Establishment units

Physical locations of this company

Registered office

Av la Douce Colline 22

1420 Braine-l'Alleud

2.233.641.764

Leopold III-laan 5

1030 Schaarbeek

Active since 16 June 2003

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0859.704.565
VAT number: BE 0859.704.565
Registered office: Av la Douce Colline 22, 1420 Braine-l'Alleud
Names & denominations: MA-EL RX
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 16 June 2003
Peppol: Not registered
Activities · NACE: Activiteiten van medisch specialisten

View on CBE Public ↗ Annual accounts (NBB) ↗